Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

The introduction of chemoimmunotherapy and more recently the implementation of novel agents into first-line and relapse treatment have substantially improved treatment outcomes in patients with chronic lymphocytic leukaemia (CLL). With longer progression-free survival and more frequently observed de...

Descripción completa

Detalles Bibliográficos
Autores principales: Fürstenau, Moritz, De Silva, Nisha, Eichhorst, Barbara, Hallek, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919470/
https://www.ncbi.nlm.nih.gov/pubmed/31942542
http://dx.doi.org/10.1097/HS9.0000000000000287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919470/
https://www.ncbi.nlm.nih.gov/pubmed/31942542
http://dx.doi.org/10.1097/HS9.0000000000000287

Ejemplares similares